DF 003
Alternative Names: DF-003Latest Information Update: 29 Sep 2025
At a glance
- Originator Drug Farm
- Class Anti-inflammatories; Cardiovascular therapies; Eye disorder therapies; Small molecules; Urologics
- Mechanism of Action ALPK1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders; Renal failure; Retinal disorders
Most Recent Events
- 23 Sep 2025 Drug Farm enters into an agreement with Cincinnati Children's Hospital Medical Center (CCHMC) to provide DF 003 for research into its therapeutic benefits for diseases related to clonal hematopoiesis of indeterminate potential (CHIP)
- 09 Sep 2025 Pharmacodynamics and pharmacokinetics data from a preclinical study in Retinal disorders released by Drug Farm
- 29 May 2025 Pharmacokinetics and adverse event data from a phase I trial in Renal failure released by Drug Farm